Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) may do more than improve the function of a faulty protein in people with cystic fibrosis (CF). According to a new study from Italy, the triple-combination therapy may also help reduce chronic inflammation, known to contribute to long-term lung damage in those with CF.